Ipamorelin

Ipamorelin

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) and selective ghrelin receptor agonist, developed by Novo Nordisk as part of a programme to identify GHS compounds with improved selectivity profiles. It is structurally related to GHRP-1 and GHRP-2 but is distinguished by its high selectivity for the GH secretagogue receptor (GHSR-1a) with minimal off-target activity at cortisol, prolactin, or ACTH release pathways — a key pharmacological advantage that makes it a cleaner research tool for studying GH axis stimulation compared to earlier GHRPs. Ipamorelin has been extensively studied in preclinical research for its effects on GH and IGF-1 secretion, body composition, bone density, and gastrointestinal motility.

Mechanism of Action

Ipamorelin acts as a potent, selective agonist of GHSR-1a, the ghrelin receptor expressed in the hypothalamus, pituitary somatotrophs, and peripheral tissues. GHSR-1a activation stimulates pulsatile GH release from pituitary somatotrophs via Gq/11-mediated phospholipase C activation and intracellular calcium mobilisation, as well as Gi-mediated cAMP modulation. Unlike GHRP-2 and GHRP-6, Ipamorelin does not significantly stimulate cortisol or ACTH release at GH-stimulating doses, and has minimal effect on prolactin secretion, reflecting its high receptor selectivity. The resulting GH pulses drive hepatic IGF-1 production, mediating downstream anabolic, lipolytic, and tissue-remodelling effects. Ipamorelin also acts synergistically with GHRH analogues (such as CJC-1295 or Sermorelin), as the two pathways converge on somatotroph GH release through complementary mechanisms.

Research Applications

• GHSR-1a pharmacology and selective GHS receptor agonism studies
• GH and IGF-1 axis stimulation and somatotropic signalling research
• Body composition, lean mass, and adipose tissue metabolism investigation
• Bone mineral density and skeletal remodelling preclinical models
• Gastrointestinal motility and GHS receptor peripheral function research

Specifications

• Molecular Formula: C₃₈H₄₉N₉O₅
• Molecular Weight: 711.9 g/mol
• CAS Number: 170851-70-4
• Purity: ≥98%
• Form: Lyophilised powder
• Storage: -20°C
• Shelf Life: 24 months

Commonly Stacked With

Ipamorelin is most commonly co-investigated with GHRH analogues for synergistic GH axis stimulation. Available combinations include CJC-1295 (No DAC) + Ipamorelin (pre-formulated blend), CJC-1295 (No DAC), and CJC-1295 (With DAC). Also studied alongside GHRP-6 Acetate for comparative GHS receptor research.

This peptide is supplied as a lyophilised powder and requires reconstitution with Bacteriostatic Water prior to use.

This product is intended for legitimate laboratory and analytical research use only. Not for human use, veterinary use, or consumer use. Not for diagnostic or therapeutic purposes.